350 reports of this reaction
1.1% of all ATOMOXETINE reports
#17 most reported adverse reaction
ALOPECIA is the #17 most commonly reported adverse reaction for ATOMOXETINE, manufactured by Aurobindo Pharma Limited. There are 350 FDA adverse event reports linking ATOMOXETINE to ALOPECIA. This represents approximately 1.1% of all 30,444 adverse event reports for this drug.
Patients taking ATOMOXETINE who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a less commonly reported adverse event for ATOMOXETINE, but still significant enough to appear in the safety profile.
In addition to alopecia, the following adverse reactions have been reported for ATOMOXETINE:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 350 FDA reports for ATOMOXETINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 1.1% of all adverse event reports for ATOMOXETINE, making it a notable side effect.
If you experience alopecia while taking ATOMOXETINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.